Analysis of RET promoter CpG island methylation using methylation-specific PCR (MSP), pyrosequencing, and methylation-sensitive high-resolution melting (MS-HRM): impact on stage II colon cancer patient outcome.

Date publication

janvier 2016

Journal

Clinical epigenetics

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CHAPUSOT Caroline , Dr JOOSTE Valérie

Tous les auteurs :
Draht MX, Smits KM, Jooste V, Tournier B, Vervoort M, Ramaekers C, Chapusot C, Weijenberg MP, van Engeland M, Melotte V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27118999

Résumé

Already since the 1990s, promoter CpG island methylation markers have been considered promising diagnostic, prognostic, and predictive cancer biomarkers. However, so far, only a limited number of DNA methylation markers have been introduced into clinical practice. One reason why the vast majority of methylation markers do not translate into clinical applications is lack of independent validation of methylation markers, often caused by differences in methylation analysis techniques. We recently described RET promoter CpG island methylation as a potential prognostic marker in stage II colorectal cancer (CRC) patients of two independent series.

Mots clés

Aged, Colorectal Neoplasms, genetics, CpG Islands, DNA Methylation, Female, Humans, Male, Polymerase Chain Reaction, methods, Prognosis, Promoter Regions, Genetic, Proto-Oncogene Proteins c-ret, genetics, Sensitivity and Specificity, Sequence Analysis, DNA, methods, Survival Analysis

Référence

Clin Epigenetics. 2016 ;8:44